Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Matteo LazzeroniMatteo PuntoniAliana Guerrieri-GonzagaDavide SerranoLuca BoniTania Buttiron WebberMarianna FavaIrene Maria BriataLivia GiordanoMaria DigennaroLaura CortesiFabio FalciniPatrizia SerraFranca AvinoFrancesco MilloKatia CagossiElisa GalleraniAlessia De SimoneAnna CarielloGiuseppe AprileMaria RenneBernardo BonanniAndrea DecensiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tamoxifen 5 mg once daily for 3 years significantly prevents recurrence from noninvasive breast cancer after 7 years from treatment cessation without long-term adverse events.